Generic Name and Formulations:
Ambenonium chloride 10mg; tabs.
Indications for MYTELASE:
Individualize. Usual range: 5–25mg 3 or 4 times daily. Increase gradually at intervals of 1–2 days. Some patients may require 50–75mg per dose. Increasing dosage above 200mg daily requires supervision by clinician aware of signs and treatment of overdose.
Concomitant atropine, mecamylamine, or any other ganglionic blocking agents.
Monitor closely; narrow margin between first appearance of side effects and serious toxic effects. Asthma. Parkinson's disease. Mechanical intestinal or urinary obstruction. Bradycardia. Cardiac conduction disorders. Elderly. Pregnancy. Nursing mothers: not recommended.
Overdosage (eg, excessive salivation, abdominal cramps, diarrhea, miosis, urinary urgency, sweating, nausea, increase in bronchial and lacrymal secretions, vomiting, muscle cramps, fasciculation of voluntary muscles, generalized malaise, anxiety, vertigo).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|